NASACORT HFA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NASACORT HFA (NASACORT HFA).
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators (e.g., cytokines, prostaglandins) and reducing nasal inflammation.
| Metabolism | Primarily metabolized by CYP3A4 isoenzyme; undergoes first-pass metabolism in the liver. |
| Excretion | Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites and parent drug) |
| Half-life | Terminal elimination half-life is approximately 3.5 hours following intranasal administration, reflecting slow systemic absorption and prolonged local retention. |
| Protein binding | Approximately 71% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 203 L (2.9 L/kg based on 70 kg body weight), indicating extensive tissue distribution. |
| Bioavailability | Absolute intranasal bioavailability is approximately 49%, due to partial absorption from the nasal mucosa and first-pass metabolism. |
| Onset of Action | Onset of clinical effect (symptom relief) typically occurs within 12 hours after the first intranasal dose, though maximal benefit may require several days. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily dosing, allowing for sustained control of allergic rhinitis symptoms. |
| Molecular Weight | 434.5 |
55 mcg (1 spray) per nostril once daily; may increase to 110 mcg (2 sprays) per nostril once daily if needed. Maximum 440 mcg/day total.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | 2-11 years: 55 mcg (1 spray) per nostril once daily; maximum 110 mcg (2 sprays) per nostril once daily. Children >=12 years: same as adult. |
| Geriatric use | No specific dose adjustment; use caution due to potential for increased systemic effects, but no dose reduction routinely recommended. |
| 1st trimester | Insufficient human data; animal studies show no teratogenicity; corticosteroids are generally avoided unless benefits outweigh risks. |
| 2nd trimester | No evidence of harm in humans; use only if clearly needed. |
| 3rd trimester | No evidence of harm; may cause fetal adrenal suppression with chronic high doses, but intranasal use has minimal systemic absorption. |
Clinical note
Comprehensive clinical and safety monograph for NASACORT HFA (NASACORT HFA).
| Placental transfer | Minimal due to low systemic bioavailability (<1%) after intranasal administration; triamcinolone acetonide is lipid-soluble and may cross if systemically absorbed, but typical doses yield negligible transfer. |
| Breastfeeding | Minimal systemic absorption via intranasal route; unlikely to affect breastfeeding infant. Use caution with high doses or prolonged therapy. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Hypersensitivity to triamcinolone acetonide or any excipientUntreated nasal mucosal infections (e.g., herpes simplex)
| Precautions | Risk of Candida albicans infection in nose and pharynx., Nasal septal perforation (rare) with prolonged use., Systemic corticosteroid effects (e.g., growth suppression in children, glaucoma, hypercorticism) when used at higher doses., Immune suppression: Increased susceptibility to infections., Avoid use in patients with recent nasal trauma, surgery, or ulcers. |
| Food/Dietary | No known food interactions. Avoid concurrent use of grapefruit juice? Not applicable; triamcinolone acetonide nasal spray has minimal systemic absorption. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L2 |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal studies, triamcinolone acetonide caused fetal toxicity (cleft palate, skeletal abnormalities) at doses ≥ 0.02 times the maximum recommended human intranasal dose (MRHID). Intranasal corticosteroids are generally considered low risk for teratogenicity when used at therapeutic doses, but first-trimester exposure should be minimized. Insufficient data for second and third trimesters; fetal growth may be affected with chronic high-dose systemic exposure. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression with prolonged high-dose use. Fetal growth and development should be assessed during routine prenatal visits; consider ultrasound if prolonged use of high doses. Neonates exposed in utero should be monitored for adrenal insufficiency if maternal dose was high. |
| Fertility Effects | Triamcinolone acetonide at systemic doses has been shown to impair fertility in animal studies (e.g., prolonged estrous cycle, reduced conception rates). No human data on fertility effects with intranasal use; effects are unlikely at recommended intranasal doses due to minimal systemic absorption. |
| Clinical Pearls | Nasacort HFA (triamcinolone acetonide) is a intranasal corticosteroid spray for allergic rhinitis. Priming is essential after 2 weeks of non-use – discard if unused beyond 2 weeks. Avoid spraying directly onto the nasal septum to prevent irritation and bleeding. Use consistent daily dosing for maximum efficacy; onset of action is 12–24 hours with peak benefit in 1–2 weeks. Monitor for epistaxis, especially in pediatric patients. No systemic glucocorticoid effects expected at recommended doses. |
| Patient Advice | Use exactly one spray in each nostril once daily; do not exceed recommended dose. · Shake the canister gently before each use. · Prime the spray by actuating 5 times into the air if new or not used for 2 weeks. · Blow your nose gently before use, then insert nozzle into nostril aiming away from the septum. · Do not use for more than 6 months without consulting your doctor. · Common side effects include mild nosebleeds, nasal irritation, and headache. · This medication may not provide immediate relief; continue regular use for full benefit. |